Microcap Ledger Yarrow Bioscience, Inc. $YARW
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- New Haven, CT
- Fiscal year end
- December 31
- Shares outstanding
- 2,669,746 [10-Q 2026-08-13]
What the company doesAI summary of filing
VYNE Therapeutics is a clinical-stage biopharmaceutical company developing small molecule BET inhibitors for immune-mediated inflammatory conditions. The company has exclusive worldwide rights to research, develop, and commercialize BET inhibitor compounds licensed from Tay Therapeutics. VYNE is currently developing two product candidates: repibresib gel, a topically administered pan-BD BET inhibitor that failed its Phase 2b trial in nonsegmental vitiligo in July 2025, and VYN202, an oral BD2-selective BET inhibitor currently in clinical development for immune-mediated diseases after a Phase 1b psoriasis trial was terminated. The company is pre-revenue and is pursuing a merger with Yarrow Biosciences, which would shift its focus to advancing Yarrow's lead program, YB-101, a TSHR antibody for Graves Disease and Thyroid Eye Disease. [10-K 2026-02-27]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $183.0K | −$6.59M | −$6.07M | $22.93M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $570.0K | −$26.48M | −$33.12M | $24.03M | [S-4/A 2026-06-03] |
| FY ended Dec 2024 | $501.0K | −$39.83M | −$33.97M | $19.93M | [S-4/A 2026-06-03] |
- Quarterly cash burn
- −$3.04M
- Cash runway Estimate
- ~22.6 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-08-07 | 14,749,397 | [10-Q 2024-08-14] |
| 2024-11-01 | 14,751,433 | [10-Q 2024-11-07] |
| 2025-02-27 | 15,209,862 | [10-K 2025-03-06] |
| 2025-05-01 | 16,664,892 | [10-Q 2025-05-08] |
| 2025-08-07 | 25,472,165 | [10-Q 2025-08-14] |
| 2026-02-12 | 33,323,171 | [10-K 2026-02-27] |
| 2026-05-01 | 33,352,858 | [10-Q 2026-05-15] |
| 2026-08-10 | 2,669,746 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2024-03-01; declared effective 2026-08-19 [S-3 2024-03-01]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-03-11. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-03-11 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-03-11] |
| 2025-09-12 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-09-12] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-29 | Rtw Fund Group Gp, Llc | other | 133,290 | — | [4 2026-07-30] |
| 2026-07-23 | Zeronda Tyler | other | 22,516 | $0.90 | [4 2026-07-24] |
| 2026-07-23 | Stuart Iain | other | 15,405 | $0.90 | [4 2026-07-24] |
| 2026-07-23 | Harsch Mutya | other | 22,516 | $0.90 | [4 2026-07-24] |
| 2026-07-23 | Domzalski David | other | 79,391 | $0.90 | [4 2026-07-24] |
| 2026-06-30 | Zeronda Tyler | other | 3,464 | $0.65 | [4 2026-07-02] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-07 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-09-17 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-09-14 | 8-K | Material agreement entered |
| 2026-09-11 | 424B5 | Prospectus or prospectus supplement |
| 2026-09-11 | 424B5 | Prospectus or prospectus supplement |
| 2026-09-10 | 8-K | Other events |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-07 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $YARW
Email me when Yarrow Bioscience, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.